Merck & Co., Inc. (NYSE:MRK) Shares Sold by CCM Investment Advisers LLC

Share on StockTwits

CCM Investment Advisers LLC lowered its position in Merck & Co., Inc. (NYSE:MRK) by 4.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 152,271 shares of the company’s stock after selling 6,485 shares during the period. Merck & Co., Inc. comprises approximately 2.1% of CCM Investment Advisers LLC’s holdings, making the stock its 16th largest position. CCM Investment Advisers LLC’s holdings in Merck & Co., Inc. were worth $12,818,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. grew its stake in Merck & Co., Inc. by 0.8% in the 2nd quarter. Vanguard Group Inc. now owns 209,505,775 shares of the company’s stock worth $17,567,058,000 after acquiring an additional 1,694,360 shares in the last quarter. BlackRock Inc. grew its stake in Merck & Co., Inc. by 2.3% in the 2nd quarter. BlackRock Inc. now owns 191,863,408 shares of the company’s stock worth $16,087,745,000 after acquiring an additional 4,397,580 shares in the last quarter. Janus Henderson Group PLC grew its stake in Merck & Co., Inc. by 7.8% in the 2nd quarter. Janus Henderson Group PLC now owns 24,839,949 shares of the company’s stock worth $2,082,840,000 after acquiring an additional 1,790,405 shares in the last quarter. Nuveen Asset Management LLC grew its stake in Merck & Co., Inc. by 6,517.4% in the 2nd quarter. Nuveen Asset Management LLC now owns 24,307,332 shares of the company’s stock worth $2,038,169,000 after acquiring an additional 23,940,007 shares in the last quarter. Finally, Invesco Ltd. grew its stake in Merck & Co., Inc. by 18.4% in the 2nd quarter. Invesco Ltd. now owns 18,309,138 shares of the company’s stock worth $1,535,222,000 after acquiring an additional 2,843,458 shares in the last quarter. 74.53% of the stock is owned by institutional investors.

A number of equities analysts have recently issued reports on MRK shares. Credit Suisse Group reiterated a “buy” rating and set a $95.00 price objective on shares of Merck & Co., Inc. in a research note on Wednesday, August 7th. ValuEngine downgraded shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Leerink Swann started coverage on shares of Merck & Co., Inc. in a research note on Thursday, August 15th. They set an “outperform” rating and a $103.00 price objective on the stock. Bank of America started coverage on shares of Merck & Co., Inc. in a research note on Wednesday, October 16th. They issued a “neutral” rating and a $90.00 target price for the company. Finally, Morgan Stanley raised their target price on shares of Merck & Co., Inc. from $90.00 to $95.00 and gave the company an “overweight” rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, three have issued a hold rating and thirteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $95.47.

Shares of NYSE MRK traded up $1.29 during trading on Wednesday, hitting $88.67. The company had a trading volume of 6,959,728 shares, compared to its average volume of 9,951,397. The stock has a fifty day simple moving average of $84.76 and a two-hundred day simple moving average of $83.76. Merck & Co., Inc. has a fifty-two week low of $70.89 and a fifty-two week high of $88.73. The firm has a market capitalization of $225.80 billion, a price-to-earnings ratio of 20.43, a price-to-earnings-growth ratio of 1.89 and a beta of 0.52. The company has a quick ratio of 0.98, a current ratio of 1.26 and a debt-to-equity ratio of 0.84.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, October 29th. The company reported $1.51 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.24 by $0.27. The business had revenue of $12.40 billion for the quarter, compared to analyst estimates of $11.59 billion. Merck & Co., Inc. had a net margin of 20.26% and a return on equity of 48.16%. The company’s revenue for the quarter was up 14.9% compared to the same quarter last year. During the same quarter last year, the business earned $1.19 earnings per share. On average, analysts anticipate that Merck & Co., Inc. will post 5.15 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 8th. Investors of record on Monday, December 16th will be given a dividend of $0.61 per share. The ex-dividend date is Friday, December 13th. This is a positive change from Merck & Co., Inc.’s previous quarterly dividend of $0.55. This represents a $2.44 dividend on an annualized basis and a yield of 2.75%. Merck & Co., Inc.’s payout ratio is presently 50.69%.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Recommended Story: Current Ratio

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.